Cohen & Steers Inc. (CNS)
| Bid | 65.74 |
| Market Cap | 3.91B |
| Revenue (ttm) | 525.41M |
| Net Income (ttm) | 151.26M |
| EPS (ttm) | 3.06 |
| PE Ratio (ttm) | 25.09 |
| Forward PE | 19.77 |
| Analyst | Hold |
| Ask | 89.02 |
| Volume | 146,418 |
| Avg. Volume (20D) | 226,052 |
| Open | 76.70 |
| Previous Close | 76.32 |
| Day's Range | 75.24 - 77.67 |
| 52-Week Range | 67.09 - 110.67 |
| Beta | 1.44 |
About CNS
Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries...
Analyst Forecast
According to 2 analyst ratings, the average rating for CNS stock is "Hold." The 12-month stock price forecast is $90, which is an increase of 17.20% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumSAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
2 months ago · accessnewswire.com
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ ListingCash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopha...